161 related articles for article (PubMed ID: 16193240)
1. Phase I trial of oral talactoferrin alfa in refractory solid tumors.
Hayes TG; Falchook GF; Varadhachary GR; Smith DP; Davis LD; Dhingra HM; Hayes BP; Varadhachary A
Invest New Drugs; 2006 May; 24(3):233-40. PubMed ID: 16193240
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
Jonasch E; Stadler WM; Bukowski RM; Hayes TG; Varadhachary A; Malik R; Figlin RA; Srinivas S
Cancer; 2008 Jul; 113(1):72-7. PubMed ID: 18484647
[TBL] [Abstract][Full Text] [Related]
3. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.
Hayes TG; Falchook GS; Varadhachary A
Invest New Drugs; 2010 Apr; 28(2):156-62. PubMed ID: 19238327
[TBL] [Abstract][Full Text] [Related]
4. Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors.
Spadaro M; Curcio C; Varadhachary A; Cavallo F; Engelmayer J; Blezinger P; Pericle F; Forni G
Cancer Res; 2007 Jul; 67(13):6425-32. PubMed ID: 17616703
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R
J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509
[TBL] [Abstract][Full Text] [Related]
6. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S; Crawford J; Chang A; Manegold C; Perez-Soler R; Douillard JY; Thatcher N; Barlesi F; Owonikoko T; Wang Y; Pultar P; Zhu J; Malik R; Giaccone G;
Ann Oncol; 2013 Nov; 24(11):2875-80. PubMed ID: 24050956
[TBL] [Abstract][Full Text] [Related]
7. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Riess JW; Bhattacharya N; Blenman KR; Neal JW; Hwang G; Pultar P; San-Pedro Salcedo M; Engleman E; Lee PP; Malik R; Wakelee HA
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):182-6. PubMed ID: 24494587
[TBL] [Abstract][Full Text] [Related]
8. Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Madan RA; Tsang KY; Bilusic M; Vergati M; Poole DJ; Jochems C; Tucker JA; Schlom J; Giaccone G; Gulley JL
Oncologist; 2013; 18(7):821-2. PubMed ID: 23847257
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.
Guntupalli K; Dean N; Morris PE; Bandi V; Margolis B; Rivers E; Levy M; Lodato RF; Ismail PM; Reese A; Schaumberg JP; Malik R; Dellinger RP;
Crit Care Med; 2013 Mar; 41(3):706-16. PubMed ID: 23425819
[TBL] [Abstract][Full Text] [Related]
10. Talactoferrin immunotherapy in metastatic renal cell carcinoma: a case series of four long-term survivors.
Lewis MA; Hayes TG
J Clin Med Res; 2011 Feb; 3(1):47-51. PubMed ID: 22043271
[TBL] [Abstract][Full Text] [Related]
11. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study.
Lyons TE; Miller MS; Serena T; Sheehan P; Lavery L; Kirsner RS; Armstrong DG; Reese A; Yankee EW; Veves A
Am J Surg; 2007 Jan; 193(1):49-54. PubMed ID: 17188087
[TBL] [Abstract][Full Text] [Related]
12. Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.
Vincent JL; Marshall JC; Dellinger RP; Simonson SG; Guntupalli K; Levy MM; Singer M; Malik R;
Crit Care Med; 2015 Sep; 43(9):1832-8. PubMed ID: 26010687
[TBL] [Abstract][Full Text] [Related]
13. The role of talactoferrin alpha in the treatment of non-small cell lung cancer.
Kelly RJ; Giaccone G
Expert Opin Biol Ther; 2010 Sep; 10(9):1379-86. PubMed ID: 20684737
[TBL] [Abstract][Full Text] [Related]
14. Talactoferrin stimulates wound healing with modulation of inflammation.
Engelmayer J; Blezinger P; Varadhachary A
J Surg Res; 2008 Oct; 149(2):278-86. PubMed ID: 18619616
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Digumarti R; Wang Y; Raman G; Doval DC; Advani SH; Julka PK; Parikh PM; Patil S; Nag S; Madhavan J; Bapna A; Ranade AA; Varadhachary A; Malik R
J Thorac Oncol; 2011 Jun; 6(6):1098-103. PubMed ID: 21532506
[TBL] [Abstract][Full Text] [Related]
16. Oral pretreatment with recombinant human lactoferrin limits trauma-hemorrhagic shock-induced gut injury and the biological activity of mesenteric lymph.
Son JY; Chandler B; Feketova E; Qin Y; Quackenbush EJ; Deitch EA
J Surg Res; 2014 Mar; 187(1):270-7. PubMed ID: 24321622
[TBL] [Abstract][Full Text] [Related]
17. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk.
Jiang R; Du X; Lönnerdal B
J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):642-52. PubMed ID: 25000352
[TBL] [Abstract][Full Text] [Related]
19. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
20. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
